Your Article Summary
See Latest ArticlesAbbott Receives CE Mark for Company's Next-Generation XIENCE PRIME Drug Eluting Stent, Advancing Leadership Position
Abbott, 06/24/09
Abbott announced that it has received CE Mark for its next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09